| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-10-04 | Avrobio (USA - MA) GenStem Therapeutics (USA ) | AVR-RD-04 | cystinosis | licensing | Rare diseases - Genetic diseases - Lysosomal diseases | Licensing agreement |
| 2017-10-04 | BioNTech (Germany) Eufets (Germany) BioNTech Innovative Manufacturing Services (Germany) | cell and gene therapy products | establishment of a new subsidiary in the EU | Technology - Services | Establishment of a new subsidiary in the EU | |
| 2017-10-03 | Merck KGaA (Germany) | new production line at the manufacturing site of Bari | construction of new premises | Construction of new premises | ||
| 2017-10-03 | Lonza (Switzerland) Shire (UK - USA) | clinical-stage mammalian manufacturing site in Hayward (USA - CA) | plant acquisition | Technology - Services | Plant acquisition | |
| 2017-10-03 | Merck KGaA (Germany) | Modugno-Bari production site | construction of new premises | Technology - Services | Construction of new premises | |
| 2017-10-02 | Transgene (France) Randox (UK) | oncolytic immunotherapies using Transgene’sviral platform Invir.IO™ and Randox’s SdAbs (single-domain antibodies) | development - collaboration | Cancer - Oncology | Development agreement | |
| 2017-10-02 | KSQ Therapeutics (USA - MA) | chief executive officer - chief scientific officer | nomination | Cancer - Oncology | Nomination | |
| 2017-09-29 | TG Therapeutics (USA - NY) Fast Forward (USA - NY) | TGR-1202 (umbralisib) | progressive multiple sclerosi | clinical research | Neurodegenerative diseases | Clinical research agreement |
| 2017-09-28 | OSE Immunotherapeutics (France) Inserm Transfert (France) | cancer immunotherapy targeting a new suppressive myeloid cell receptor (a C-type lectin receptor) | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-09-28 | Basilea Pharmaceutica (Switzerland) China Resources Gosun Pharmaceutical (China) | Zevtera®/Mabelio® (ceftobiprole) | severe community-acquired and hospital-acquired pneumonia | licensing | Infectious diseases | Licensing agreement |
| 2017-09-27 | Bavarian Nordic (Denmark) U.S. Department of Health & Human Services (HHS - USA) | Imvamune® smallpox vaccine | smallpox | supply - distribution | Infectious diseases | Distribution agreement |
| 2017-09-27 | Cancer Research UK (CRUK) (UK) Glythera (UK) | CDK11 inhibitor payload series for the development of antibody drug conjugates | licensing | Cancer - Oncology | Licensing agreement | |
| 2017-09-26 | OSE Immunotherapeutics (France) Selexis (Switzerland) | research cell banks (RCBs) from the Selexis SUREtechnology Platform™ | services contract | Technology - Services | Services contract | |
| 2017-09-26 | Confo Therapeutics (Belgium) Lundbeck (Denmark) | small molecule therapeutic compounds acting upon two G-protein coupled receptors (GPCRs) | research - R&D | Neurological diseases - Psychiatric diseases | Research agreement | |
| 2017-09-26 | Bicycle Therapeutics (UK - USA) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2017-09-25 | Tapimmune (USA - FL) | nomination | Cancer - Oncology | Nomination | ||
| 2017-09-21 | Juno Therapeutics (USA - WA) | headquarters and research facility | opening of new premises | Cancer - Oncology | Opening of new premises | |
| 2017-09-20 | Enterome Bioscience (France) | research laboratories in Genopole | opening of new premises | Autoimmune diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Opening of new premises | |
| 2017-09-20 | Enterome Bioscience (France) | opening of new premises | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases | Opening of new premises | ||
| 2017-09-20 | Synpromics (UK) Solid Biosciences (USA - MA) | muscle-selective promoter candidates | Duchenne muscular dystrophy (DMD) | research - R&D | Rare diseases - Genetic diseases - Neuromuscular diseases | Research agreement |
